Minimal engineering resolves prevalent off-target binding in clinical antibodies

Computationally engineered Fab interfaces eliminate light chain mispairing in IgG-like bispecifics

High-throughput in vitro data and modeling streamline PK prediction and antibody lead prioritization

Engineered CD3 antibodies with low polyreactivity enable safer, more stable bispecific therapeutics

Engineered antibody ADG-2 neutralizes diverse sarbecoviruses, offering broad coronavirus protection

Study shows improved specificity comes with lower stability, informing antibody engineering strategies